Gluco-Rite - General Information:
An oral hypoglycemic agent which is rapidly absorbed and completely metabolized. [PubChem]
Gluco-Rite, a second-generation sulfonylurea, is used with diet to lower blood glucose in patients with diabetes mellitus type II. The primary mode of action of glipizide in experimental animals appears to be the stimulation of insulin secretion from the beta cells of pancreatic islet tissue and is thus dependent on functioning beta cells in the pancreatic islets. In humans glipizide appears to lower the blood glucose acutely by stimulating the release of insulin from the pancreas, an effect dependent upon functioning beta cells in the pancreatic islets. In man, stimulation of insulin secretion by glipizide in response to a meal is undoubtedly of major importance. Fasting insulin levels are not elevated even on long-term glipizide administration, but the postprandial insulin response continues to be enhanced after at least 6 months of treatment. Some patients fail to respond initially, or gradually lose their responsiveness to sulfonylurea drugs, including glipizide.
Gluco-Rite for patients
Glipizide is a sulfonylurea used in patients with diabetes mellitus to lower blood sugar. Notify your physician if you are pregnant or nursing. Do not change the dose or stop taking glipizide without talking with your physician. Immediate-release glipizide tablets should be taken on an empty stomach, 30 minutes before a meal. Extended-release glipizide tablets may be taken with food. Do not break, crush, or chew extended-release glipizide tablets. Patients taking extended release glipizide tablets may notice something that looks like a tablet in their stool. This is the leftover tablet after the medicine has been absorbed and is normal. Avoid drinking alcohol while taking this medication. Alcohol may cause flushing, weakness, dizziness, a tingling sensation and headache. Avoid taking aspirin with this medication. Notify your physician if you develop unexplained fever, sore throat, yellowing of the skin or eyes, dark urine, or skin rash. Notify your physician if you develop fatigue, nausea, confusion, agitation, excessive hunger, profuse sweating, numbness or tingling of lips, tongue or extremities (may indicate low blood sugar), or if you develop excessive thirst or urination, or glucose or ketones in the urine or blood (may indicate high blood sugar).
Immediate and Extended Release Tablets
The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents, some azoles and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents. When such drugs are administered to a patient receiving glipizide, the patient should be observed closely for hypoglycemia. When such drugs are withdrawn from a patient receiving glipizide, the patient should be observed closely for loss of control. In vitro binding studies with human serum proteins indicate that glipizide binds differently than tolbutamide and does not interact with salicylate or dicumarol. However, caution must be exercised in extrapolating these findings to the clinical situation and in the use of glipizide with these drugs.
Certain drugs tend to produce hyperglycemia and may lead to loss of control. These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid. When such drugs are administered to a patient receiving glipizide, the patient should be closely observed for loss of control. When such drugs are withdrawn from a patient receiving glipizide, the patient should be observed closely for hypoglycemia.
A potential interaction between oral miconazole and oral hypoglycemic agents leading to severe hypoglycemia has been reported. Whether this interaction also occurs with the intravenous, topical, or vaginal preparations of miconazole is not known. The effect of concomitant administration of fluconazole and glipizide has been demonstrated in a placebo-controlled crossover study in normal volunteers. All subjects received glipizide alone and following treatment with 100 mg of fluconazole as a single daily oral dose for seven days. The mean percentage increase in the glipizide AUC after fluconazole administration was 56.9% (range: 35 to 81).
Immediate and Extended Release Tablets
Glipizide is contraindicated in patients with:
1. Known hypersensitivity to the drug.
2. Diabetic ketoacidosis, with or without coma. This condition should be treated with insulin.
Other Brand Names containing Glipizide:
Aldiab; Digrin; Dipazide; Glibenese; Glibetin; Glican; Glide; Glidiab; Glipid; Glipizide Extended-Release Tablets; Gluco-Rite; Glucolip; Glucotrol; Glucotrol XL; Glucozide; Glupitel; Glupizide; Glyde; Melizide; Metaglip; Mindiab; Minidab; Minidiab; Minodiab; Napizide; Ozidia; Sucrazide;
Indication, Mechanism Of Action, Drug Interactions, Food Interactions, etc..